Seres Therapeutics, Inc.

NasdaqGS:MCRB Rapporto sulle azioni

Cap. di mercato: US$131.2m

Seres Therapeutics Gestione

Gestione criteri di controllo 3/4

Seres Therapeutics Il CEO è Eric Shaff, nominato in Jan2019, e ha un mandato di 5.75 anni. la retribuzione annua totale è $ 3.16M, composta da 21.7% di stipendio e 78.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.086% delle azioni della società, per un valore di $ 112.58K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.1 anni e 8.1 anni.

Informazioni chiave

Eric Shaff

Amministratore delegato

US$3.2m

Compenso totale

Percentuale dello stipendio del CEO21.7%
Mandato del CEO5.8yrs
Proprietà del CEO0.09%
Durata media del management5.1yrs
Durata media del Consiglio di amministrazione8.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 23

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Jul 13
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

May 08
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Aug 09
Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Dec 28
Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Sep 01
Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Aug 19

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Aug 03

Seres Therapeutics: The Good And The Challenging

Jul 12

Seres Therapeutics stock slips on $100M stock offering

Jun 30

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Jun 16
Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

Jun 09

Seres Therapeutics Is Playing A Long Game

Mar 06

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Dec 27
Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Seres Therapeutics Molecular Data On SER-109 Looks Good

Oct 04

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Eric Shaff rispetto agli utili di Seres Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$162m

Mar 31 2024n/an/a

-US$83m

Dec 31 2023US$3mUS$685k

-US$114m

Sep 30 2023n/an/a

-US$141m

Jun 30 2023n/an/a

-US$153m

Mar 31 2023n/an/a

-US$265m

Dec 31 2022US$4mUS$662k

-US$250m

Sep 30 2022n/an/a

-US$231m

Jun 30 2022n/an/a

-US$103m

Mar 31 2022n/an/a

-US$87m

Dec 31 2021US$10mUS$625k

-US$66m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$132m

Mar 31 2021n/an/a

-US$105m

Dec 31 2020US$3mUS$590k

-US$89m

Sep 30 2020n/an/a

-US$90m

Jun 30 2020n/an/a

-US$76m

Mar 31 2020n/an/a

-US$66m

Dec 31 2019US$2mUS$540k

-US$70m

Sep 30 2019n/an/a

-US$73m

Jun 30 2019n/an/a

-US$78m

Mar 31 2019n/an/a

-US$95m

Dec 31 2018US$1mUS$435k

-US$99m

Sep 30 2018n/an/a

-US$107m

Jun 30 2018n/an/a

-US$92m

Mar 31 2018n/an/a

-US$92m

Dec 31 2017US$2mUS$377k

-US$89m

Compensazione vs Mercato: La retribuzione totale di Eric ($USD 3.16M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 650.00K ).

Compensazione vs guadagni: La retribuzione di Eric è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Eric Shaff (48 yo)

5.8yrs

Mandato

US$3,158,336

Compensazione

Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer at Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Eric Shaff
President5.8yrsUS$3.16m0.086%
$ 112.6k
Lisa von Moltke
Executive VP & Chief Medical Officer4.6yrsUS$1.57m0.012%
$ 16.2k
Teresa Young
Executive VP and Chief Commercial & Strategy Officer4.3yrsUS$1.82m0.047%
$ 61.8k
Marella Thorell
Executive VP & CFOless than a yearNessun datoNessun dato
David Ege
Executive VP & Chief Technology Officer4yrsUS$5.32m0.046%
$ 59.8k
Matthew Henn
Executive VP & Chief Scientific Officer5.7yrsUS$1.67m0.040%
$ 51.9k
Carlo Tanzi
Investor Relations Officer8.9yrsNessun datoNessun dato
Thomas DesRosier
Chief Legal Officer8.4yrsUS$1.44m0.073%
$ 95.8k
Caroline Holda
Assistant General Counselno dataNessun datoNessun dato

5.1yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di MCRB è esperto e expertise (durata media dell'incarico 5.1 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Eric Shaff
President5.8yrsUS$3.16m0.086%
$ 112.6k
Willard Dere
Independent Director7.3yrsUS$225.23k0.019%
$ 24.5k
Dennis Ausiello
Independent Director9.5yrsUS$222.27k0%
$ 0
Kurt Graves
Independent Director8.9yrsUS$219.23k0%
$ 0
Richard Kender
Independent Director10yrsUS$232.69k0.037%
$ 49.0k
Mark Wilcox
Member of Scientific Advisory Board9.8yrsNessun datoNessun dato
Andrew Goodman
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Curtis Huttenhower
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Paul Biondi
Independent Director4.6yrsUS$211.73k0.028%
$ 36.7k
Stephen Berenson
Independent Chairman5.2yrsUS$249.23k0.0021%
$ 2.8k
Robert Jenq
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Elhanan Borenstein
Member of Scientific Advisory Boardno dataNessun datoNessun dato

8.1yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MCRB sono considerati esperti (durata media dell'incarico 8.1 anni).